A drug tested in patients with advanced lung cancer has failed to increase the chances of survival. Nexavar (sorafenib), made by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, is already approved by the Food and Drug Administration (FDA) to treat some forms of liver and kidney cancer. Researchers had hoped the medication would also benefit patients with advanced relapsed or refractory non-squamous non-small cell lung cancer whose disease had progressed after previous treatments. The drug, however, did not meet the goal of improving overall survival in patients with late-stage lung cancer.
The study involved more than 700 people with the disease, and compared Nexavar with a placebo. While the overall survival goal was not achieved, researchers did see an improvement in a secondary goal of progression-free survival, or the time from the start of treatment until the patient’s cancer starts advancing or the patient dies.
Lung cancer is the most common cancer in the world, with about 1.2 million new cases diagnosed each year. Non-small cell lung cancer is the most common type of the disease. Patients with late-stage lung cancer or those whose cancer has returned are almost never cured. The goals of therapy are to extend and improve quality of life.
Source: CBS News